Select a State

Global health R&D delivers for Massachusetts

US government investment in global health R&D has delivered

$731.1 million
to Massachusetts research institutions
8,400+ new jobs
for Massachusetts

Neglected diseases in Massachusetts

Chikungunya cases
234
Dengue cases
33
HIV diagnoses
6,241
Malaria cases
388
Tuberculosis cases
1,916
West Nile cases
88
Zika cases
129
--

Massachusetts's top USG-funded global health R&D institutions

Harvard University (including School of Public Health, Public Health AIDS Initiative, and Harvard Medical School)
$135.0 million
Massachusetts General Hospital (including CAMtech and Center for Integration of Medicine & Innovative Technology)
$93.4 million
Beth Israel Deaconess Medical Center
$89.8 million
Brigham and Women's Hospital
$82.3 million
University of Massachusetts Medical School
$80.4 million
Broad Institute
$44.1 million
Children's Hospital Boston (including Children's Hospital Corporation and Immune Disease Institute)
$51.8 million
Tufts University (including Tufts Medical Center)
$34.4 million
Dana-Farber Cancer Institute
$32.0 million
Boston University (including Boston University Medical Campus and Center for Global Health and Development)
$24.3 million
Boston Medical Center
$13.1 million
Massachusetts Institute of Technology
$9.7 million
Brandeis University
$6.5 million
Northeastern University
$6.0 million
Whitehead Institute for Biomedical Research
$5.6 million
Fenway Health
$4.4 million
The Forsyth Institute
$4.1 million
Harvard Pilgrim Health Care, Inc.
$3.9 million
University of Massachusetts Amherst
$2.9 million
Novartis Vaccines Institute for Global Health
$2.2 million
The Home for Little Wanderers including Boston Children's Services
$1.7 million
Worcester Polytechnic Institute
$1.2 million
Boston Biomedical Research Institute
$731 thousand
Boston College
$532 thousand
Clark University
$394 thousand
Howard M. Shapiro
$331 thousand
University of Massachusetts Boston
$300 thousand

Massachusetts industry in global health R&D

AbbVie
Location(s):
Worcester
Affinivax
Location(s):
Cambridge
Alere
Location(s):
Waltham
Amgen
Location(s):
Cambridge, Woburn
Astellas
Location(s):
Cambridge, Marlborough
AstraZeneca
Location(s):
Waltham
Beckman Coulter
Location(s):
Danvers
Bristol-Myers Squibb
Location(s):
Cambridge, Devens, Waltham
Celgene
Location(s):
Cambridge
Charles River Laboratories
Location(s):
Shrewsburg, Wilmington, Woburn, Worcester
Disease Diagnostic Group
Location(s):
Cambridge
Eli Lilly and Company
Location(s):
Cambridge
EMD Serono
Location(s):
Billerica, Rockland
Emergent Biosolutions
Location(s):
Canton
Genocea Biosciences
Location(s):
Cambridge
GSK
Location(s):
Cambridge
Merck & Co
Location(s):
Boston
Microbiotix
Location(s):
Worcester
Nanbiosym
Location(s):
Cambridge
Novartis
Location(s):
Cambridge
Oxford Immunotec
Location(s):
Boston, Marlborough, Norwood
Pfizer
Location(s):
Andover, Cambridge
Quidel
Location(s):
Beverly
Quigen
Location(s):
Waltham, Mansfield
Sanofi
Location(s):
Allston, Cambridge, Framingham, Northborough, Waltham
Sarepta Therapeutics
Location(s):
Andover, Cambridge
Transgene
Location(s):
Cambridge

Massachusetts's top areas of global health R&D by USG funding

38.7%
HIV/AIDS
6.5%
Malaria
25.8%
Tuberculosis
12.3%
Diarrheal diseases
1.8%
Bacteria pneumonia & meningitis
10.1%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
Leprosy
Trachoma
4.7%
Other
Ebola/viral hemorrhagic fevers
Hepatitis C
Non-allocable
Salmonella infections

Global health R&D at work in Massachusetts

Researchers from Harvard Medical School, Partners In Health, and Boston Children’s Hospital have shown that a new commercially developed rapid test for Ebola, performed at the point of care, was as effective as a conventional laboratory-based method. The successful field trial is a potential gamechanger. A test that can accurately diagnose Ebola within minutes provides clinicians with crucial information for treating patients and containing outbreaks.

Footnotes